Download Files:
Toyocamycin
$50 – $450
Products Details
Product Description
– Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM[1][2][3].
Web ID
– HY-103248
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Cancer-Kinase/protease
Molecular Formula
– C12H13N5O4
References
– [1]Pandey S, et al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel). 2022 Jul 8;14(14):3340. |[2]Park SG, et al. Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells. Pharmacol Rep. 2017 Feb;69(1):90-96.|[3]Toyocamycin, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79.
CAS Number
– 606-58-6
Molecular Weight
– 291.26
Compound Purity
– 99.90
SMILES
– O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C3=C(C(N)=NC=N3)C(C#N)=C2
Clinical Information
– No Development Reported
Research Area
– Cancer; Infection
Solubility
– DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Antibiotic;Apoptosis;CDK;Fungal;IRE1
Isoform
– CDK2;CDK4;CDK6;CDK7;CDK9
Pathway
– Anti-infection;Apoptosis;Cell Cycle/DNA Damage
Product type
– Natural Products
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
